Bordeaux, Nouvelle-Aquitaine, France
Explicyte Immuno-Oncology is a preclinical & translational CRO specialized in Immuno-Oncology. Our expertise and capacities encompass : - Cell-based assays for drug screening - In vivo tumor models of immune checkpoint inhibition (CTLA-4, PD-1, PD-L1) - Patient sample analysis for the validation of new targets & biomarkers (flow cytometry, digital pathology, and multi-omics analysis) https://explicyte.com/
ImmuSmol helps scientists to visualize & quantify small molecules with easy-to-use and validated immunoassays. Starting with the development of anti-hapten antibodies targeting kynurenine metabolites, we expanded our product portfolio with primary antibodies and ELISA kits to neurotransmitters and amino acids, with a focus on dopamine and arginine metabolism. Our company now serves over >1,000 scientists worldwide, and our antibodies & ELISA kits were cited in over 200 publications. https://www.immusmol.com/
“Evaluating the role of a new tryptophan catabolite in Amyotrophic Lateral Sclerosis” under the supervision of Gilles Guillemin.
“Deciphering the role of Indoleamine 2,3 dioxygenase in the control of the innate immune response” under the supervision of Francesca Fallarino & Bernard Veyret (University of Bordeaux)